← All peptidesBlends
Semaglutide + Cagrilintide (CagriSema)
Semaglutide + Cagrilintide ("CagriSema")
GLP-1 agonist plus amylin analog mirroring the investigational CagriSema combination for appetite and weight endpoints.
Typical dose
0.25–2.4 mg
Frequency
Once weekly (titrated)
Half-life
—
Route
subcutaneous
Typical vial sizes
10 mg20 mg
Sample reconstitution
10 mg vial · 2 mL bac water · 1.325 mg dose
- Draw volume
- 0.265 mL
- Insulin units
- 27 units
- Concentration
- 5.00 mg/mL
- Doses per vial
- 7.5
Research notes
As sold: Semaglutide 5mg + Cagrilintide 5mg (1:1). ~16-week titration ladder from 0.25mg toward ~2.4mg per component.
Further reading
- Published research on Semaglutide + Cagrilintide (CagriSema) (PubMed) →
- Clinical trials for Semaglutide + Cagrilintide (CagriSema) (ClinicalTrials.gov) →
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.